The corporate stated it is going to begin provide of speedy point-of-care nasopharyngeal swab assessments from this week.
Drug main Cipla on Wednesday introduced its partnership with the Premier Medical Company Non-public Restricted for commercialisation of the speedy antigen check kits for coronavirus (COVID-19) in India.
“On this collaboration, Cipla will probably be liable for the advertising and marketing and distribution of the Speedy Antigen Detection Take a look at for the qualitative detection of SARS-CoV-2 antigen that will probably be manufactured by Premier Medical Company Non-public Restricted,” Cipla stated in a regulatory submitting.
The corporate stated it is going to begin provide of speedy point-of-care nasopharyngeal swab assessments from this week. The check will probably be marketed beneath the model title ‘CIPtest.’ Shares of Cipla have been buying and selling 0.29% increased at ₹783.95 a chunk on the BSE.